{"nctId":"NCT00245570","briefTitle":"Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)","startDateStruct":{"date":"2005-12"},"conditions":["Asthma, Exercise-Induced"],"count":47,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Montelukast","Drug: Comparator: Salmeterol","Drug: Comparator: Placebo (montelukast)","Drug: Comparator: Placebo (salmeterol)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Montelukast","Drug: Comparator: Salmeterol","Drug: Comparator: Placebo (montelukast)","Drug: Comparator: Placebo (salmeterol)"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Montelukast","Drug: Comparator: Salmeterol","Drug: Comparator: Placebo (montelukast)","Drug: Comparator: Placebo (salmeterol)"]},{"label":"4","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Montelukast","Drug: Comparator: Salmeterol","Drug: Comparator: Placebo (montelukast)","Drug: Comparator: Placebo (salmeterol)"]},{"label":"5","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Montelukast","Drug: Comparator: Salmeterol","Drug: Comparator: Placebo (montelukast)","Drug: Comparator: Placebo (salmeterol)"]},{"label":"6","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Montelukast","Drug: Comparator: Salmeterol","Drug: Comparator: Placebo (montelukast)","Drug: Comparator: Placebo (salmeterol)"]}],"interventions":[{"name":"Comparator: Montelukast","otherNames":[]},{"name":"Comparator: Salmeterol","otherNames":[]},{"name":"Comparator: Placebo (montelukast)","otherNames":[]},{"name":"Comparator: Placebo (salmeterol)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Physician-diagnosed exercise-induced bronchospasm\n\nExclusion Criteria:\n\n* Patient is, other than asthma, not in good, stable health. The Primary Investigator will evaluate whether there are other reasons why the patient may not participate.","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"45 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Post-dose in Patients With Exercise-Induced Bronchoconstriction (EIB)","description":"In patients with EIB, the percent change from pre-exercise baseline FEV1 to the lowest FEV1 within 60 minutes after exercise challenge (2 hours post-dose). The FEV1 measurement obtained 5 minutes before the exercise challenge was the baseline, and was specific to each exercise challenge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.15","spread":"10.28"},{"groupId":"OG001","value":"10.46","spread":"9.95"},{"groupId":"OG002","value":"21.86","spread":"13.44"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Requiring β-Agonist Rescue Medication After Exercise Challenge at 2 Hours Postdose","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Requiring β-Agonist Rescue Medication After Exercise Challenge at 8.5 Hours Postdose","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Requiring β-Agonist Rescue Medication After Exercise Challenge at 24 Hours Postdose","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Percent Fall in FEV1 After Exercise Challenge at 8.5 Hours Post-dose in Patients With EIB","description":"In patients with EIB, the percent change from pre-exercise baseline FEV, to the lowest FEV1 within 60 minutes after exercise challenge (8.5 hours post-dose). The FEV1 measurement obtained 5 minutes before the exercise challenge was the baseline, and was specific to each exercise challenge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.60","spread":"9.64"},{"groupId":"OG001","value":"11.01","spread":"7.56"},{"groupId":"OG002","value":"16.65","spread":"12.76"}]}]}]},{"type":"SECONDARY","title":"Maximum Percent Fall in FEV1 After Exercise Challenge at 24 Hours Post-dose in Patients With EIB","description":"In patients with EIB, the percent change from pre-exercise baseline FEV, to the lowest FEV1 within 60 minutes after exercise challenge (24 hours post-dose). The FEV1 measurement obtained 5 minutes before the exercise challenge was the baseline, and was specific to each exercise challenge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.09","spread":"11.10"},{"groupId":"OG001","value":"16.22","spread":"13.09"},{"groupId":"OG002","value":"13.64","spread":"9.67"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve for FEV1 Percent Change From Preexercise Baseline During the 60 Minutes Following Exercise Challenge (AUC 0-60 Min) at 2 Hours Postdose","description":"The measure included only the area below the pre-exercise\n\nbaseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"254.60","spread":"241.17"},{"groupId":"OG001","value":"293.05","spread":"362.33"},{"groupId":"OG002","value":"710.43","spread":"529.91"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve for FEV1 Percent Change From Preexercise Baseline During the 60 Minutes Following Exercise Challenge (AUC 0-60 Min) at 8.5 Hours Postdose","description":"The measure included only the area below the pre-exercise baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191.01","spread":"166.24"},{"groupId":"OG001","value":"276.26","spread":"226.37"},{"groupId":"OG002","value":"511.28","spread":"566.30"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve for FEV1 Percent Change From Preexercise Baseline During the 60 Minutes Following Exercise Challenge (AUC 0-60 Min) at 24 Hours Postdose","description":"The measure included only the area below the pre-exercise baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"231.09","spread":"413.73"},{"groupId":"OG001","value":"554.93","spread":"649.52"},{"groupId":"OG002","value":"395.96","spread":"464.92"}]}]}]},{"type":"SECONDARY","title":"Time to Recovery From Maximum Percentage Decrease in FEV1 After Exercise Challenge at 2 Hours Postdose","description":"The time to recovery from maximum percent fall is the duration between the time at which the maximum percent fall in FEV1 after exercise challenge occurs and the time when FEV1 returns to within 5% of the preexercise baseline for the first time.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.63","spread":"23.72"},{"groupId":"OG001","value":"17.58","spread":"27.81"},{"groupId":"OG002","value":"42.70","spread":"34.26"}]}]}]},{"type":"SECONDARY","title":"Time to Recovery From Maximum Percentage Decrease in FEV1 After Exercise Challenge at 8.5 Hours Postdose","description":"The time to recovery from maximum percent fall is the\n\nduration between the time at which the maximum percent fall in FEV1 after exercise challenge occurs and the\n\ntime when FEV1 returns to within 5% of the preexercise baseline for the first time.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.70","spread":"13.38"},{"groupId":"OG001","value":"13.82","spread":"18.37"},{"groupId":"OG002","value":"32.34","spread":"34.57"}]}]}]},{"type":"SECONDARY","title":"Time to Recovery From Maximum Percentage Decrease in FEV1 After Exercise Challenge at 24 Hours Postdose","description":"The time to recovery from maximum percent fall is the\n\nduration between the time at which the maximum percent fall in FEV1 after exercise challenge occurs and the\n\ntime when FEV1 returns to within 5% of the preexercise baseline for the first time.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.04","spread":"20.84"},{"groupId":"OG001","value":"29.75","spread":"33.50"},{"groupId":"OG002","value":"23.31","spread":"29.30"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":[]}}}